01.07.2010 | Research Articles
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2010
Einloggen, um Zugang zu erhalten